As aforementioned, mounting clinical studies have confirmed the outstanding prognostic effects of ERCC1 in cervical cancer, thus the development of immunotherapy by targeting ERCC1 (i.e., ERCC1 inhibitor) may have important implications for modulating the antitumor immune responses in patients with advanced cervical cancer. Here, ERCC1 is linked to cervical carcinoma.